Next-generation sequencing (NGS) applications found that innate drive gene mutations affect PD-L1 expression and TMB, which may contribute to primary or adaptive resistance to immunotherapy in NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.